MedTrace Logo

Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia

NCT04094207 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-10-25

No results posted yet for this study

Summary

The aim of this study to evaluate the efficacy and safety of pentoxifylline, the novel phosphodiesterase inhibitor, as an adjunctive to risperidone in alleviating the negative symptoms of schizophrenia.

Conditions

Interventions

DRUG

Placebo oral tablet

Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day

DRUG

Pentoxifylline

Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day

Sponsors & Collaborators

  • Sadat City University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-09-30
Completion
2022-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04094207 on ClinicalTrials.gov